Northern Trust Corp Editas Medicine, Inc. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 737,345 shares of EDIT stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

737,345

Previous 832,880 11.47%

Holding current value

$2.57 Million

Previous $6.18 Million 44.28%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $446,148 - $695,494	-95,535 Reduced 11.47%	737,345 $3.44 Million
Q1 2024 May 14, 2024	SELL	$7.03 - $11.07 $260,728 - $410,564	-37,088 Reduced 4.26%	832,880 $6.18 Million
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $117,362 - $208,623	-18,778 Reduced 2.11%	869,968 $8.81 Million
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $862,488 - $1.16 Million	124,637 Added 16.31%	888,746 $6.93 Million
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $600,892 - $1.08 Million	94,480 Added 14.11%	764,109 $6.29 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $43,747 - $71,751	-6,223 Reduced 0.92%	669,629 $4.85 Million
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $825,477 - $1.31 Million	-99,216 Reduced 12.8%	675,852 $5.99 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.48 Million - $2.36 Million	121,703 Added 18.63%	775,068 $9.49 Million
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $166,363 - $355,541	-16,653 Reduced 2.49%	653,365 $7.73 Million
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $337,441 - $662,180	-23,966 Reduced 3.45%	670,018 $12.7 Million
Q4 2021 Feb 08, 2022	SELL	$26.55 - $40.57 $381,842 - $583,477	-14,382 Reduced 2.03%	693,984 $18.4 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $724,570 - $1.35 Million	-18,451 Reduced 2.54%	708,366 $29.1 Million
Q2 2021 Aug 13, 2021	SELL	$31.29 - $56.64 $1.06 Million - $1.91 Million	-33,754 Reduced 4.44%	726,817 $41.2 Million
Q1 2021 May 12, 2021	SELL	$39.71 - $90.58 $418,741 - $955,166	-10,545 Reduced 1.37%	760,571 $31.9 Million
Q4 2020 Feb 11, 2021	SELL	$27.07 - $84.35 $628,673 - $1.96 Million	-23,224 Reduced 2.92%	771,116 $54.1 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $871,010 - $1.15 Million	31,041 Added 4.07%	794,340 $22.3 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $2.46 Million - $4.56 Million	132,894 Added 21.08%	763,299 $22.6 Million
Q1 2020 May 14, 2020	BUY	$14.88 - $32.78 $222,009 - $489,077	14,920 Added 2.42%	630,405 $12.5 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $22,510 - $37,687	1,155 Added 0.19%	615,485 $18.2 Million
Q3 2019 Nov 13, 2019	BUY	$22.49 - $26.81 $1.29 Million - $1.54 Million	57,343 Added 10.3%	614,330 $14 Million
Q2 2019 Aug 13, 2019	BUY	$20.48 - $27.76 $184,606 - $250,228	9,014 Added 1.64%	556,987 $13.8 Million
Q1 2019 May 13, 2019	BUY	$19.43 - $26.41 $33,691 - $45,794	1,734 Added 0.32%	547,973 $13.4 Million
Q4 2018 Feb 12, 2019	BUY	$18.19 - $31.79 $37,180 - $64,978	2,044 Added 0.38%	546,239 $12.4 Million
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $592,622 - $822,812	21,433 Added 4.1%	544,195 $17.3 Million
Q2 2018 Sep 18, 2018	SELL	$31.4 - $41.01 $92,441 - $120,733	-2,944 Reduced 0.56%	522,762 $18.7 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $3.32 Million - $4.34 Million	105,845 Added 25.21%	525,706 $18.8 Million
Q1 2018 May 09, 2018	BUY	$29.84 - $44.08 $1.38 Million - $2.04 Million	46,354 Added 12.41%	419,861 $13.9 Million
Q4 2017 Feb 14, 2018	SELL	$21.89 - $31.34 $70,814 - $101,384	-3,235 Reduced 0.86%	373,507 $11.5 Million
Q3 2017 Nov 13, 2017	BUY	$15.81 - $24.01 $5.96 Million - $9.05 Million	376,742	376,742 $9.05 Million

Others Institutions Holding EDIT

# of Institutions

252

Shares Held

58.7M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $240M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Editas Medicine, Inc. Transaction History